Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CANF · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe… NCT07410455 · Lowe Syndrome Piclidenoson | CANF Can-Fite BioPharma | Phase 2 | Not yet recruiting | 5 | Aug 31, 2027 | Registry ↗ |
| Apr 29, 2025 | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Effica… NCT06643260 · Plaque Psoriasis piclidenoson, Placebo | CANF Can-Fite BioPharma | Phase 3 | Not yet recruiting | 705 | Dec 2027 | Registry ↗ |
| Apr 29, 2025 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class… NCT05201404 · Hepatocellular Carcinoma, Cirrhosis Namodenoson, Placebo | CANF Can-Fite BioPharma | Phase 3 | Recruiting | 471 | Feb 2026 | Registry ↗ |
| Jan 31, 2025 | Namodenoson Treatment of Advanced Pancreatic Cancer NCT06387342 · Pancreatic Adenocarcinoma, Pancreatic Cancer Namodenoson 25mg | CANF Can-Fite BioPharma | Phase 2 | Recruiting | 20 | Jul 15, 2026 | Registry ↗ |
| Jul 31, 2024 | Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) NCT04697810 · NASH - Nonalcoholic Steatohepatitis Namodenoson, Placebo | CANF Can-Fite BioPharma | Phase 2 | Unknown | 114 | Apr 15, 2025 | Registry ↗ |
| Sep 18, 2023 | Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients NCT00280917 · Rheumatoid Arthritis CF101 | CANF Can-Fite BioPharma | Phase 2 | Completed | 254 | Apr 2007 | Registry ↗ |
| Feb 8, 2023 | Safety and Efficacy Study of CF101 to Treat Psoriasis NCT00428974 · Plaque Psoriasis CF101 1mg, CF101 2mg | CANF Can-Fite BioPharma | Phase 2 | Completed | 76 | Sep 2009 | Registry ↗ |
| Oct 4, 2022 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepato… NCT02128958 · Hepatocellular Carcinoma CF102, Placebo | CANF Can-Fite BioPharma | Phase 2 | Completed | 78 | Nov 27, 2017 | Registry ↗ |
| Jun 30, 2022 | Trial of CF101 to Treat Patients With Dry Eye Disease NCT01235234 · Keratoconjunctivitis Sicca CF101 | CANF Can-Fite BioPharma | Phase 3 | Completed | 236 | Nov 2013 | Registry ↗ |
| Jun 28, 2022 | CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis NCT03168256 · Plaque Psoriasis CF101 2mg, CF101 3mg | CANF Can-Fite BioPharma | Phase 3 | Completed | 528 | Jan 6, 2022 | Registry ↗ |
| May 24, 2022 | Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis NCT01034306 · Rheumatoid Arthritis CF101, Placebo control | CANF Can-Fite BioPharma | Phase 2 | Completed | 79 | Dec 2013 | Registry ↗ |
| May 17, 2022 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma NCT00790218 · Hepatocellular Carcinoma CF102 | CANF Can-Fite BioPharma | Phase 1/2 | Completed | 19 | Dec 2012 | Registry ↗ |
| May 12, 2022 | Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressu… NCT01033422 · Ocular Hypertension, Glaucoma CF101, Placebo for | CANF Can-Fite BioPharma | Phase 2 | Completed | 89 | Dec 2016 | Registry ↗ |
| May 9, 2022 | Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca NCT00349466 · Keratoconjunctivitis Sicca CF101, Placebo | CANF Can-Fite BioPharma | Phase 2 | Completed | 80 | May 2009 | Registry ↗ |
| Apr 22, 2022 | Piclidenoson for Treatment of COVID-19 NCT04333472 · COVID-19, Coronavirus Infection Piclidenoson, Placebo | CANF Can-Fite BioPharma | Phase 2 | Completed | 6 | Mar 6, 2022 | Registry ↗ |
| Dec 19, 2020 | CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis NCT02647762 · Rheumatoid Arthritis CF101 1 mg, CF101 2 mg | CANF Can-Fite BioPharma | Phase 3 | Terminated | 244 | Nov 30, 2020 | Registry ↗ |
| Nov 18, 2020 | Trial of CF101 to Treat Patients With Psoriasis NCT01265667 · Plaque Psoriasis CF101, Placebo | CANF Can-Fite BioPharma | Phase 2/3 | Completed | 293 | Mar 2015 | Registry ↗ |
| Mar 17, 2020 | A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease NCT02927314 · Non-alcoholic Steatohepatitis (NASH) CF102, Placebo | CANF Can-Fite BioPharma | Phase 2 | Completed | 60 | Mar 1, 2020 | Registry ↗ |
| Mar 29, 2018 | Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients NCT00556894 · Rheumatoid Arthritis CF101, Placebo | CANF Can-Fite BioPharma | Phase 2 | Completed | 253 | Mar 2009 | Registry ↗ |
| Feb 1, 2018 | Safety &Efficacy of CF101 to Subjects With Uveitis NCT01905124 · Uveitis, Posterior, Uveitis, Intermediate CF101, Placebo | CANF Can-Fite BioPharma | Phase 2 | Withdrawn | 0 | Sep 2019 | Registry ↗ |
| Feb 1, 2018 | A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee NCT00837291 · Osteoarthritis of the Knee CF101, Placebo | CANF Can-Fite BioPharma | Phase 2 | Withdrawn | 0 | Dec 2018 | Registry ↗ |
| Apr 15, 2015 | A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 NCT00790673 · Chronic Hepatitis C CF 102, Placebo | CANF Can-Fite BioPharma | Phase 1/2 | Completed | 32 | Jun 2011 | Registry ↗ |
22 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:27 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances